Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:36 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1245

Shown on this page

Current sort

Live official records

Conditions: Type 2 Diabetes
Interventions: Ultrasound Delivery; Device
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury
Interventions: portable MRI scanner; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
Interventions: Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 25 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 3 more

Conditions: Brain and Central Nervous System Tumors
Interventions: concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2029
U.S. locations: 271
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more

Conditions: PTCL
Interventions: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 6
States / cities: Long Beach, California • New Haven, Connecticut • New York, New York + 3 more

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Echocardiography Test, Multigated Acquisition Scan, Uproleselan; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 188
States / cities: Little Rock, Arkansas • Clovis, California • La Jolla, California + 147 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions: TAK-881, HYQVIA, SC Investigational Needle Sets; Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab, placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 78
States / cities: Coronado, California • Irvine, California • La Jolla, California + 60 more

Conditions: Pelvic Floor Disorder, Pelvic Floor Muscle Exercise
Interventions: Pelvic Floor Muscle Therapy Website; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ovarian Cancer, Solid Tumor
Interventions: CUSP06; Drug
Lead sponsor: OnCusp Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Denver, Colorado • New Haven, Connecticut • Miami Beach, Florida + 9 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

Ultrasound Effects on Glycemic Control in T2DM

Identification of Brain Injury Using Portable MRI

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Video-Based Pelvic Floor Muscle Therapy

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

About this Yale institution page